Colorectal cancer screening rates are similar among older adults despite varying 10-year mortality risks, UT Southwestern Medical Center researchers report in a study. The findings, published in The American Journal of Gastroenterology, challenge conventional age-based recommendations for CRC screening that don’t take into account factors like individual life expectancies and comorbidities.
Recent research reveals that with each subsequent generation of Mexican Americans, the risk of developing liver cancer has climbed.
FDA approved Xtandi (enzalutamide) for non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
FDA has granted Breakthrough Therapy Designation to epcoritamab-bysp, an investigational T-cell engaging bispecific antibody administered subcutaneously, for relapsed or refractory follicular lymphoma.
The National Cancer Institute approved the following clinical research studies last month.
Invoking the Defense Production Act, President Joe Biden has ordered federal agencies and artificial intelligence companies to create safeguards and standards for the technology that has the capacity to uplift humankind as much as it can wreak unimaginable harm.
As a data scientist and software engineer, Razik Yousfi builds artificial intelligence models in health care. He started doing this 15 years ago, long before advanced chatbots catapulted AI into the layman’s consciousness.
President Joe Biden on Nov. 17 announced his intent to appoint W. Kimryn Rathmell as NCI director.
The FDA Oncologic Drugs Advisory Committee earlier this week was asked to review two of the slowest-moving confirmatory trials.
Experts in pharmacology and lung cancer urged physicians to prescribe the Amgen agent Lumakras (sotorasib) at the lowest tested dose—240 mg—instead of the four times higher dose of 960 mg recommended by the sponsor.
